
Home / News
-
-

-
4 Blood Typing Reagents and its Technology Development Direction and Status of Market Development 4.1 Main Products and Manufacturers of Domestic Blood Typing Reagents At present, domestic blood ty..2026-05-19View More
-
-
-

-
Original from: PR Newswire AstraZeneca and Roche Diagnostics Asia Pacific today announced a three-year Memorandum of Understanding to help advance digital pathology capabilities and elevate cancer care a..2026-05-19View More
-
-
-

-
RealBio and Thermo Fisher Scientific Partner on IVD Quality Control Solutions On May 12 in Shanghai, RealBio signed a strategic agreement with Thermo Fisher Scientific to collaborate on co..2026-05-18View More
-
-
-

-
Original from: Co-Diagnostics Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic..2026-05-18View More
-
-
-

-
Original from: Natera Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Signatera CDx as ..2026-05-18View More
-
-
-

-
Original from: PR Newswire - Labcorp's full test menu will be available through Epic's Aura platform - Integration builds on the successful deployment of Invitae genetic testing and accelerates acc..2026-05-15View More
-
-
-

-
Original from: Lucid Diagnostics Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:..2026-05-15View More
-
-
-

-
Original from: PR Newswire Cepheid, a Danaher company, announced today that it has received CE marking under the in vitro medical device regulation (IVDR) for the Xpert GI Panel. This multiplex PCR test ..2026-05-14View More
-
-
-

-
Original from: business news - Delivers the only FDA-cleared ChLIA testosterone testing portfolio with direct measurement of total testosterone, free testosterone, and sex hormone-binding globulin ..2026-05-14View More
-
-
-

-
Original from: Waters Corporation First Quarter 2026 Highlights - Total reported revenue of $1.267 billion exceeded the high end of the guidance range by $56 million, driven by strong outperformanc..2026-05-13View More
-
-
-

-
Original from: Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received CE Mark for Elecsys® pTau217, a blood test developed in collaboration with Eli Lilly and Company and desig..2026-05-13View More
-
-
-

-
As of 30 April 2026, a total of 86 China-listed companies related to the In Vitro Diagnostics (IVD) sector had released their 2025 annual reports, including 61 companies primarily engaged in IVD businesses and 25 comp..2026-05-12View More
-
-
-

-
Sansure Biotech Partners with Tencent Health to Launch an AI Ecosystem for China Primary Healthcare On May 9, Sansure Biotech signed a strategic cooperation agreement with Tencent Health at..2026-05-12View More
-
-
-

-
3.3.2 Future Development of Blood Typing Instruments Working Party on Clinical Transfusion Management, Chinese Society of Blood Transfusion investigated blood transfusion departments of 2309 hospitals in differe..2026-05-12View More
-
-
-

-
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA).2026-05-12View More
-
-
-

-
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026.2026-05-12View More
-
-
-

-
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2026.2026-05-11View More
-
-
-

-
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026.2026-05-11View More
-
-
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
-

-
Original from: Roche - PathAI¡¯s best-in-class Image Management System (IMS) with advanced AI analysis and workflow capabilities will complement Roche's digital pathology portfolio to drive laboratory eff..2026-05-08View More
-
-
-

-
Original from: Siemens Healthineers Siemens Healthineers AG today announces its results for the second quarter of fiscal year 2026 ended March 31, 2026. Q2 Fiscal Year 2026 • Eq..2026-05-08View More
-

- CAIVD WeChat
Subscription Account

- CAIVD WeChat
Channels
China Association of In-vitro Diagnostics
Part of the information in our website is from the internet.
If by any chance it violates your rights, please contact us.

